These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 30845227)
1. Prevalence and determinants of non-adherence to Imatinib in the first 3-months treatment among newly diagnosed Ethiopian's with chronic myeloid leukemia. Mulu Fentie A; Tadesse F; Engidawork E; Gebremedhin A PLoS One; 2019; 14(3):e0213557. PubMed ID: 30845227 [TBL] [Abstract][Full Text] [Related]
2. Comprehensive Evaluation of Adherence to Therapy, Its Associations, and Its Implications in Patients With Chronic Myeloid Leukemia Receiving Imatinib. Unnikrishnan R; Veeraiah S; Mani S; Rajendranath R; Rajaraman S; Vidhubala Elangovan GS; Radhakrishnan V; Ganesan TS; Sagar TG; Ganesan P Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):366-371.e3. PubMed ID: 27052853 [TBL] [Abstract][Full Text] [Related]
3. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting. Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991 [TBL] [Abstract][Full Text] [Related]
4. Initiation of generic imatinib may improve medication adherence for patients with chronic myeloid leukemia. Cole AL; Jazowski SA; Dusetzina SB Pharmacoepidemiol Drug Saf; 2019 Nov; 28(11):1529-1533. PubMed ID: 31507005 [TBL] [Abstract][Full Text] [Related]
5. Good adherence to imatinib therapy among patients with chronic myeloid leukemia--a single-center observational study. Jönsson S; Olsson B; Söderberg J; Wadenvik H Ann Hematol; 2012 May; 91(5):679-685. PubMed ID: 22048790 [TBL] [Abstract][Full Text] [Related]
6. Drug therapy problems, medication adherence and treatment satisfaction among diabetic patients on follow-up care at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. Demoz GT; Berha AB; Alebachew Woldu M; Yifter H; Shibeshi W; Engidawork E PLoS One; 2019; 14(10):e0222985. PubMed ID: 31574113 [TBL] [Abstract][Full Text] [Related]
7. Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia. Lam MS; Cheung N J Oncol Pharm Pract; 2016 Dec; 22(6):741-748. PubMed ID: 26419691 [TBL] [Abstract][Full Text] [Related]
8. Lack of congruence between patients' and health professionals' perspectives of adherence to imatinib therapy in treatment of chronic myeloid leukemia: A qualitative study. Wu S; Chee D; Ugalde A; Butow P; Seymour J; Schofield P Palliat Support Care; 2015 Apr; 13(2):255-63. PubMed ID: 24524212 [TBL] [Abstract][Full Text] [Related]
9. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Cohen MH; Johnson JR; Pazdur R Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523 [TBL] [Abstract][Full Text] [Related]
10. Side effects and medication adherence of tyrosine kinase inhibitors for patients with chronic myeloid leukemia in Taiwan. Tsai YF; Huang WC; Cho SF; Hsiao HH; Liu YC; Lin SF; Liu TC; Chang CS Medicine (Baltimore); 2018 Jun; 97(26):e11322. PubMed ID: 29953021 [TBL] [Abstract][Full Text] [Related]
12. [Analysis of efficacy and related factors in 85 chronic myeloid leukemia patients treated with imatinib mesylate]. Zhou KS; Wang YY; Zhao YZ; Yi SH; Qian LS; Wang GR; Yu Z; Wang Y; Wang JX; Qiu LG Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):208-12. PubMed ID: 20137149 [TBL] [Abstract][Full Text] [Related]
13. Predictive parameters for imatinib failure in patients with chronic myeloid leukemia. Lekovic D; Gotic M; Milic N; Zivojinovic B; Jovanovic J; Colovic N; Milosevic V; Bogdanovic A Hematology; 2017 Sep; 22(8):460-466. PubMed ID: 28327053 [TBL] [Abstract][Full Text] [Related]
14. Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial. Gore L; Kearns PR; de Martino ML; Lee ; De Souza CA; Bertrand Y; Hijiya N; Stork LC; Chung NG; Cardos RC; Saikia T; Fagioli F; Seo JJ; Landman-Parker J; Lancaster D; Place AE; Rabin KR; Sacchi M; Swanink R; Zwaan CM J Clin Oncol; 2018 May; 36(13):1330-1338. PubMed ID: 29498925 [TBL] [Abstract][Full Text] [Related]
15. Study on adherence to treatment with imatinib in chronic myeloid leukaemia and its association with therapeutic response. García-Queiruga M; Martínez-López LM; Martín-Herranz MI; Seoane-Pillado T; Fernández-Gabriel E; Calleja-Chuclá T Farm Hosp; 2016 May; 40(3):141-9. PubMed ID: 27145384 [TBL] [Abstract][Full Text] [Related]
16. Cultural factors related to adherence to imatinib in CML: a Mexican perspective. Cantú-Rodríguez OG; Sánchez-Cárdenas M; Gutiérrez-Aguirre CH; Jaime-Pérez JC; Mancias-Guerra C; González-Llano O; Gómez-Almaguer D Hematology; 2015 Mar; 20(2):72-6. PubMed ID: 25034734 [TBL] [Abstract][Full Text] [Related]
17. Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment. Colombat M; Fort MP; Chollet C; Marit G; Roche C; Preudhomme C; Reiffers J; Praloran V; Mahon FX Haematologica; 2006 Feb; 91(2):162-8. PubMed ID: 16461299 [TBL] [Abstract][Full Text] [Related]
18. Patients' perceptions about diagnosis and treatment of chronic myeloid leukemia: a cross-sectional study among Brazilian patients. Hamerschlak N; Souza Cd; Cornacchioni AL; Pasquini R; Tabak D; Spector N; Steagall M Sao Paulo Med J; 2015; 133(6):471-9. PubMed ID: 25388686 [TBL] [Abstract][Full Text] [Related]
19. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase]. Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563 [TBL] [Abstract][Full Text] [Related]